NephroGenex
NephroGenex a pharmaceutical company, focuses on developing therapeutics to treat kidney disease.
Business Model:
Revenue: $4.6M
Employees: 2-10
Rankings
Industries / Tags:
Detailed NephroGenex Information
Geographic Data
Address: PO Box 400
City: Jamison
State: PA
Zip: 18929
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$6M
Raised Total:$22M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
NephroGenex a pharmaceutical company, focuses on developing therapeutics to treat kidney disease.
Contact Phone:
+16099861780
Contact Email:
NephroGenex went public on 2/11/2014 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
2/11/2014
IPO Valuation:
$106M
Ticker Symbol:
NRXGQ
IPO Price:
$12/share
Amount Raised:
$37M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2014 | IPO | $37.2M |
|
7/2007 | Series A | $0 |
BioStratum Care Capital Vanderbilt University Office of Investments BioStratum Care Capital Vanderbilt University Office of Investments |
7/2015 | Equity | $7.5M | 11/2015 | Post-IPO Equity | $5.5M | 7/2010 | Venture Round | $1M | 11/2014 | Post-IPO Equity | 1 | $12M |
East West Bank East West Bank |
7/2007 | Series A | 3 | $3.3M |
Care Capital BioStratum Vanderbilt University Office of Investments Care Capital BioStratum Vanderbilt University Office of Investments |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
